Mr. Hugh MacNaught reports

VENTRIPOINT STRENGTHENS SALES STRATEGY WITH GLOBAL EXPERTISE TO DRIVE 2025 GROWTH

Ventripoint Diagnostics Ltd. has added Karl Pringle to the company's business advisory board, to accelerate sales of Ventripoint's artificial-intelligence-powered, heart-scanning technology by hospitals and clinics around the world.

With its proprietary VMS+ platform, Ventripoint is revolutionizing cardiac diagnostics by delivering a powerful AI-driven solution that enhances echocardiography and serves as an affordable and more accessible alternative to traditional MRI scans. Following recent regulatory milestones, Ventripoint is now primed to expand its presence in key markets and drive widespread adoption

A seasoned global health technology executive, Mr. Pringle has a proven passion for driving enterprise-level digital transformation initiatives, with extensive experience in the health care space. He is adept at building high-performing sales teams that foster vibrant customer and partner ecosystems, enabling accelerated revenue growth. Mr. Pringle's approach emphasizes accountability, urgency and customer centricity, ensuring consistent results.

Known for his ability to deliver transformational results, Mr. Pringle has a remarkable record of developing and executing strategies that drive hypergrowth. His clear and transparent communication style allows him to energize sales teams, coach effectively and engage senior stakeholders with compelling value propositions and strategic deal-closing techniques.

"Karl has excelled in global sales, marketing and business development," said Ventripoint's chief executive officer, Hugh MacNaught. "With VMS+V4.0 being cleared for sale in multiple markets it is essential that we establish a strong sales trajectory in 2025. Karl's experience and insights will be extremely helpful towards achieving this goal."

Added Mr. Pringle: "Ventripoint's VMS+ technology is unique, offering an AI enhancement to echocardiography that provides a portable, inexpensive alternative to MRIs that takes only minutes. For me it is a real market disrupter which is evidenced by its stable of elite customers, and I look forward to engaging with the team to accelerate sales."

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.